# Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy

> **NCT06809751** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Mohsen Pourazizi** · enrollment: 48 (estimated)

## Conditions studied

- Central Serous Chorioretinopathy
- Melatonin
- Ocular Diseases
- Visual Acuity
- Macula Abnormality

## Interventions

- **DRUG:** melatonin 3mg
- **DRUG:** Placebo Drug

## Key facts

- **NCT ID:** NCT06809751
- **Lead sponsor:** Mohsen Pourazizi
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809751, "Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06809751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*